Low-grade serous ovarian cancer (LGSC), accounts for just 5% to 10% of all epithelial ovarian cancers, but its distinct biology makes it especially challenging to treat. While the origin of this disease has not been identified, a multitude of patients are initially diagnosed with non-invasive lesions, or so-called Serous Borderline Tumors.
This article was originally published on MedicalXpress.com